Global Mozzarella Cheese Market to Reach $60.5 Billion by 2030
The global market for Mozzarella Cheese estimated at US$37.3 Billion in the year 2022, is projected to reach a revised size of US$60.5 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2022-2030.
The global market analysis presents a comprehensive assessment of the Blocks, Shredded, Slices, Cubes, Buffalo, Cow, and Other Sources segments within the cheese industry. The report focuses on analyzing the recent, current, and future trends for these cheese products across various geographic regions. The study covers sales analysis in terms of US$ million for the years 2022 through 2030, shedding light on the growth trajectory and potential opportunities in the market.
Blocks, one of the segments analyzed in the report, is projected to record a 6.8% CAGR and reach US$24.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Shredded segment is readjusted to a revised 6.3% CAGR for the next 8-year period.
The Mozzarella Cheese market in the U.S. is estimated at US$9.3 Billion in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.4 Billion by the year 2030.
Additionally, the report offers insights into the percentage breakdown of value sales for these cheese segments across different regions, providing a 16-year perspective for the years 2014, 2023, and 2030. This analysis aids in understanding market dynamics and trends, enabling informed decision-making within the cheese industry.
MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?
World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
COVID-19 Impact on Mozzarella Cheese Market
CHEESE – AN OVERVIEW
Mozarella Cheese – One of the Fastest Growing Cheese Types
Mozzarella Cheese – Global Key Competitors Percentage Market Share in 2022 (E)
Mozzarella Cheese Competitor Market Share Scenario Worldwide (in %): 2020E
Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
GLOBAL MARKET OVERVIEW
Mozzarella Cheese Market Set to Witness Rapid Growth
Developed Regions Hold the Largest Share, Developing to Exhibit Fastest Growth
Competition
World Mozzarella Cheese Market (2020): Market Share of Leading Players
Recent Market Activity
MARKET TRENDS & DRIVERS
Health-Conscious Trend Sheds Focus on Health Benefits of Mozzarella Cheese
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Global Annual Medical Cost of Cardiovascular Diseases in the United States: 2015-2030
Growing Demand from Diabetic Population Drives Mozzarella Cheese Market
Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
Increasing Trend of Snacking Drives Market Demand
More Innovative Cheese Snacks
The Latest formats
Growing Use of Mozzarella Cheese in Pizzas and Pastas
Increasing Manufacture of Low-Fat Organic Mozzarella Cheese
Increasing Number of Quick Service Restaurants (QSRs) to Drive the Demand for Mozzarella Cheese
Global Fast Food & Quick Service Restaurant Market Size (in US$ Billion) for 2019, 2022 & 2025
Expanding Middle Class Population in Emerging Markets Offer Increased Growth Prospects
Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020E & 2030P
Expanding Urban Population Spurs Growth
Urban Population as a % of Total Population by Geographic Region for the Years 1990, 2015 & 2050
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact: Research and Markets Laura Wood, Senior Manager [email protected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
TAMPA, Fla., Sept. 5, 2023 /PRNewswire/ — In honor of September being Childhood Cancer Awareness Month, the National Pediatric Cancer Foundation’s annual Restaurants for Research campaign is raising funds for pediatric cancer research, supporting local businesses, and uniting some of Tampa’s favorite restaurants.
Local restaurant staples are hosting different promotions to support critical research being conducted by the National Pediatric Cancer Foundation.
Cancer warrior King walks the runway during his dream walk as a chef, accompanied by professional chefs!
Participating Restaurants & Promotions
American Social 20% of total purchase donated when NPCF Mentioned on September 6
CD Roma Restaurant 20% of total sales donated on September 6
Oronzo Round-up donation campaign from September 6-30
Blind Tiger (all locations) $1 donated from every Dirty Thaiger sold through September
BluWave Sushi Round-up donation campaign through September
Grove Soho Round-up donation campaign & 50% of proceeds from Soho Sunshine Shot through September
Haven $3 from a special happy hour burger through September
MacDinton’s Irish Pub Round-up donation campaign & 50% of proceeds from Soho Sunshine Shot through September
The inspiration for Restaurants for Research was ignited from the dreams of pediatric cancer warriors all over the country who aspire to grow up and become chefs, like King.
When you donate to NPCF, you’re funding critical research and scientific advances to find better treatment options through the best doctors and scientists at over thirty leading pediatric cancer institutions in the US. With only 4% of all federal funding for cancer research allocated to childhood cancer projects, NPCF seeks your help to offset this lack of funding.
Restaurants for Research has something for every palate and is the perfect way to support critical pediatric cancer research! If you are unable to visit in person, you can donate online at NationalPCF.org/donate.
About the National Pediatric Cancer Foundation: The National Pediatric Cancer Foundation (founded in 1991) is a national nonprofit organization dedicated to funding research to eliminate childhood cancer. We govern a unique, collaborative research consortium (called the Sunshine Project) consisting of physicians and scientists from over 30 of the top hospitals in the nation and collaborate to idealize and aggregate the best scientific ideas and fund innovative research. The NPCF has received a perfect 100% score for financial health and transparency and is recognized as the top-rated, 4-star cancer charity in the U.S. by Charity Navigator. For more information, visit NationalPCF.org.
NEW YORK, Sept. 5, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Baxter and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On July 28, 2022, Baxter issued a press release in which the Company lowered its earning guidance to a range of $1.82 to $1.92 per diluted share. Explaining the lower guidance, Baxter cited “ongoing supply chain challenges causing increased inflationary pressures as well as difficulty in accessing critical components along with the impact of increased prices of diesel fuel impacting freight expenses.”
On this news, Baxter’s stock price fell $7.30 per share, or 10.93%, to close at $59.50 per share on July 28, 2022.
Then, on October 27, 2022, Baxter issued a press release in which the Company again lowered its earnings guidance to a “loss of $4.52 to $4.45 per diluted share”, again citing global supply chain constraints.
On this news, Baxter’s stock price fell $3.66 per share, or 6.35%, to close at $53.97 per share on October 27, 2022.
On January 6, 2023, Baxter disclosed that it was spinning off its Renal Care and Acute Therapies global business units and simplifying its operating model and manufacturing footprint to improve operational efficiencies.
On this news, Baxter’s stock price fell $4.12 per share, or 7.84%, to close at $48.45 per share on January 6, 2023.
Finally, on February 9, 2023, Baxter reported its fourth quarter and full year 2022 financial results. The Company’s press release stated that “[o]ngoing macroeconomic challenges and supply chain headwinds continue to weigh on business performance” and stated that the Company’s full-year U.S. GAAP diluted earnings resulted in a loss of $4.83 per share.
On this news, Baxter’s stock price fell $5.54 per share, or 12.13%, to close at $40.14 per share on February 9, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
CONTACT: Robert S. Willoughby Pomerantz LLP [email protected] 888-476-6529 ext. 7980
WESTPORT, Conn., Sept. 5, 2023 /PRNewswire/ — Energy Income Partners, LLC (EIP) the fourth largest and long-time shareholder in Magellan Midstream Partners, L.P. (“Magellan”) believes that Magellan’s August 29, 2023 Presentation amounts to a series of scare tactics that present Magellan unitholders with a false choice: merge with ONEOK or else. EIP’s decision to vote against the merger is based on the financials presented by management that show definitively that Magellan is better off as a stand-alone company, and we urge our fellow unitholders to vote “no”.
EIP has released a new presentation on its website votemmp.com that addresses Magellan’s August 29, 2023 presentation which further outlines the points below.
EIP calls out Magellan Board and Management for doubling down on Magellan’s poor prospects as a standalone company formed as a partnership due to anticipated weakness in petroleum demand. Management’s assertion that its poor prospects justify this merger belies their assertions in their own 10-K released February of 2023 and their Investor Day presentation on April 2022. EIP observes that Magellan was making a public disclosure of its positive prospects AT THE SAME TIME that it was negotiating a deal that it now says is intended to stave off these dangers.
EIP shows in its presentation that Magellan has tripled its earnings over the last 15 years during which time refined petroleum demand has declined nearly 7%, disproving current management’s entire thesis regarding the impact declining petroleum demand may have on per share earnings growth.
EIP calls out Magellan on warning unitholders that the price for units and the multiples at which they trade could decline, while ignoring the tax savings that would result if the transaction were rejected.
EIP calls out Magellan for failing to conduct a fulsome sales process. If this transaction is so important to avoid the secular risks that Magellan warns about, why did Magellan only speak to one counterparty and why didn’t it conduct a broad process, and determine what other alternatives were available? A passive check following the announcement of a transaction is hardly the way to maximize value if a sale is warranted. The current narrative that the ONEOK transaction is the solution to the secular risks facing Magellan has all the appearance of an after-the-fact rationalization rather than a well-considered motivation.
EIP calls out Magellan’s Board for failing to engage with unitholders including EIP to discuss alternatives including conversion to a C-Corporation or to provide analysis other than a naked conclusion that such a transaction would be “complex” or “uneconomic.”
EIP calls out Magellan for mischaracterizing or misunderstanding EIP’s tax analysis. Their Presentation contests the truism that investors benefit from the deferral of taxes because of the time value of money. EIP has never disputed the existence of an existing tax liability only that its present value is far less than the $2.7 billion that would be due upon completion of this merger.
EIP calls out Management for not disputing the poor growth prospects for ONEOK evidenced by ONEOK’s own forecast in the S-4 of less than a 5% return on its growth capital over the next five years.
EIP has a greater belief in Magellan’s prospects than both Magellan’s Board and Management. Based on financial analysis of the information provided by ONEOK and Magellan management, it is clear that staying a stand-alone company with an appropriate analysis of alternatives such as a tax-efficient conversion to a C-Corp is better for unitholders than the proposed merger. Magellan’s own 10-K, from February of 2023, highlighted its opportunity as a standalone company to deploy capital to improve the value of its common units. Magellan is a top-tier company with excellent assets that generate stable fee-based inflation hedged income that has consistently over time supported steady growing earnings.
About Energy Income Partners, LLC
Founded in 2003, Energy Income Partners (EIP), LLC is an asset manager based in Westport, CT focusing on energy infrastructure. EIP’s team has significant experience in the energy, pipeline and utility industries. As of July 31, 2023 EIP has $5.2 billion in assets under management. www.eipinvestments.com
Disclosures:
This is not a solicitation of authority to vote your proxy. Please DO NOT send us your proxy card. Energy Income Partners, LLC is not able to vote your proxies, nor does this communication contemplate such an event. EIP urges shareholders to vote against the proposed merger or not vote which will have the same effect as voting no.
The views expressed are those of Energy Income Partners, LLC as of the date referenced and are subject to change at any time based on market or other conditions. These views are not intended to be a forecast of future events or a guarantee of future results. These views may not be relied upon as investment advice. The information provided in this material should not be considered a recommendation to buy or sell any of the securities mentioned. It should not be assumed that investments in such securities have been or will be profitable. This piece is for informational purposes and should not be construed as a research report.
Energy Income Partners, LLC conducted its own analysis based upon information available to it at the time of the analysis which may change at any time without notice and does not make any warranty as to the accuracy or completeness of any analysis, data point, assumption or opinion presented herein.
Distribution of this letter, regardless of the means or format of its delivery, does not constitute the provision of tax advice by EIP, nor should any general analysis piece be relied upon for the formulation of any targeted tax strategy. For more information regarding specific personal or corporate tax matters, including, but not limited to, personal tax implications relating to specific portfolio transactions, please consult a qualified tax professional.
JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ — Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.
Dr. Wilson pursued higher education at the prestigious University of Edinburgh in Scotland in 1971 where he earned a Bachelor of Science degree in Biochemistry. He then attended Oxford University to continue his extraordinary education where he received a Doctor of Philosophy in Molecular Biophysics in 1976 and a Doctor of Science in Biological Sciences 2000.
Dr. Wilson launched his career in 1982 when he was hired as a Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology. In this post, he directed a laboratory involved in biomedical research on infectious diseases. He currently serves as a Professor at Scripps Research (formerly The Scripps Research Institute or TSRI) in La Jolla, California. The doctor explained that Scripps Research was established in 1924 and concentrates on research and education in biomedical sciences and notably houses more than 170 laboratories on campus.
An international leader in solving the structure of influenza virus hemagglutinin, the first viral antigen structure to be determined from a membrane virus in 1981, Dr. Wilson has also extensively studied other infectious diseases and is presently investigating the immune response to SARS-CoV-2 to better understand, either by vaccination or natural infection, what types of antibodies are produced and how such information can be used to design next-generation vaccines and therapeutics. Looking to the future, he plans to continually contribute to various infectious disease projects, including finding a vaccine for the Human Immunodeficiency Virus and more universal vaccines for influenza virus and coronaviruses.
An internationally renowned scientist, Dr. Wilson is an elected member of the American Academy of Arts and Sciences (AAAS); a fellow of the Royal Society of London; an international member of the National Academy of Sciences; a corresponding fellow of the Royal Society of Edinburgh; a fellow of the American Crystallographic Association; and fellow of the American Academy of Microbiology. He is the recipient of the prestigious Newcomb Cleveland Prize for Outstanding Contribution to Science from the AAAS in 1997; has been recognized by TSRI with the First Bernie Gilula Award for Faculty Excellence in the graduate program in 2010; and a Second Outstanding Mentor Award from the Society of Fellows at TSRI in 2012. The scientist and educator was also recognized with a Peter Gorer Lectureship from the British Society for Immunology in 2000 and an honorary fellowship from Corpus Christi College in Oxford in 2009.
Dr. Wilson is an internationally known author of countless research publications in various leading scholarly journals and has served in editorial roles for several leading scholarly journals, including Science; Immunology; Journal of Experimental Medicine; and Journal of Molecular Biology.
Dedicated to excellence in his field, Dr. Wilson has served on the scientific advisory board for the Keystone Symposia from 2000 to 2017 and on its board of directors from 2008 to 2017; has been serving on the international scientific advisory board at Academia Sinica in Taipei, Taiwan, since 2015; and was active in various other capacities, including Director of the NIGMS Joint Center for Structural Genomics from 2000 to 2016.
Distinguished, world renowned experts appointed to strengthen the development of Phanes’ three clinical programs in oncology
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has formed a Clinical Advisory Board (CAB) to enhance the development of its three clinical stage programs: PT199 for solid tumors, PT886 for gastric, gastroesophageal junction and pancreatic adenocarcinomas, and PT217 for small cell lung cancer and other neuroendocrine cancers. The CAB consists of preeminent leaders with deep expertise and years of experience in their respective fields.
“We are excited to have such prominent leaders in oncology joining our Clinical Advisory Board,” said Rita Laeufle, MD, PhD, Phanes’ Chief Medical Officer. “We believe their involvement with our clinical programs reflects the significance of our mission, our science, and the promise of our cancer therapies. We will benefit considerably from access to their extensive expertise as we continue to advance our clinical programs. Phanes has built a strong pipeline, and the formation of this CAB will accelerate our efforts to help patients fighting cancer.”
Members of Phanes’ Clinical Advisory Board
Professor Dirk Arnold, M.D., Ph.D. Dirk Arnold is the Director, Asklepios Tumorzentrum Hamburg; ESMO Council member; Board member of the EORTC GI Cancer Group Steering Committee; Associate Editor for Annals of Oncology, and member of the ESMO Open Editorial Board. His main research interests include the treatment of gastrointestinal and genitourinary cancers, specifically in molecular-targeted therapies, immunotherapy, multimodal treatment strategies and early drug developments. He is a key member of several German and other international cancer societies, including the American Society of Clinical Oncology (ASCO). Professor Arnold completed his MD degree at the Universities of Ulm and Berlin in Germany, and he undertook specialist training at Charité, Humboldt University in Berlin.
Professor Tony Mok, M.D., BMSc Tony Mok is a Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. Professor Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He co-founded the Lung Cancer Research Group and served as the Associate Editor for thoracic oncology for the Journal of Clinical Oncology. Professor Mok is a Fellow of the American Society of Clinical Oncology (ASCO), a past member of ASCO Board of Directors (June 2018 – May 2022), and former President of International Association for the Study of Lung Cancer (IASLC) and received the ESMO Lifetime AchievementAward. He received his M.D. and BMSc from the University of Alberta, Canada.
Dr. Pasi Jänne, M.D., Ph.D. Dr. Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. Dr. Jänne has received several awards for his work in lung cancer including from the American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). He earned his MD and PhD from the School of Medicine at the University of Pennsylvania and completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. Dr. Jänne subsequently completed fellowship training at Dana-Farber Cancer Institute/Massachusetts General Hospital in medical oncology, and then earned a Master’s Degree in clinical investigation from Harvard University.
Dr. Kohei Shitara, M.D. Dr. Kohei Shitara is the Director of the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. He is one of the organizing members for Japanese gastric cancer treatment guidelines and is a PI and acts as a steering committee member of several ongoing global studies in the field of GI cancers. Dr. Shitara has authored more than 200 peer review publications which include approximately 100 articles as 1st author or corresponding author in major journals (NEJM, Lancet, Nature, etc.). He was recognized as one of Highly Cited Researchers by Clarivate in 2022. Dr. Shitara received his medical degree from Tohoku University School of Medicine.
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it has three assets at clinical stage, including its best-in-class monoclonal antibody (mAb) program, PT199, and two first-in-class bispecific antibody programs, PT886 and PT217.
For more information about Phanes Therapeutics, please visit www.phanesthera.com
